Randomised, double-blind, multicentre phase III trial evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with high risk of relapse, ER+ and HER2- primary breast cancer who remain free of disease.

Trial Profile

Randomised, double-blind, multicentre phase III trial evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with high risk of relapse, ER+ and HER2- primary breast cancer who remain free of disease.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Feb 2018

At a glance

  • Drugs Everolimus (Primary) ; Antineoplastics
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms PACS11UNIRAD; UNIRAD
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 02 Jun 2016 Planned End Date changed from 1 Jan 2018 to 1 Jun 1931.
    • 02 Jun 2016 Planned primary completion date changed from 1 Jan 2018 to 1 Jun 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top